SCHEMBL9913530

SCHEMBL9913530

OCc1ccccc1Cc1ccc2[nH]ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.44
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
RAD51 Q06609 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CTNNB1 P35222 2/20 0.42
WNT3A P56704 2/20 0.42
CYP17A1 P05093 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
KDM1A O60341 1/20 0.42
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
ENPP2 Q13822 1/20 0.40
AHR P35869 4/20 0.40
TRPA1 O75762 1/20 0.40
CA1 P00915 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9913549 0.84 NPC1 (0.44) NPC1USP2GAAALOX15RAD51
SCHEMBL1571266 0.84 NPC1 (0.44) NPC1USP2GAAALOX15RAD51
SCHEMBL3169603 0.82 MAOA (0.42) NPC1CTNNB1WNT3AMAOAMAOB
SCHEMBL9888410 0.82 NPC1 (0.41) NPC1USP2GAAALOX15RAD51
SCHEMBL13539226 0.82 NPC1 (0.45) NPC1CTNNB1WNT3ACYP17A1CYP11B1
SCHEMBL1570686 0.82 SLC6A2 (0.55) NPC1CTNNB1WNT3ACYP17A1CYP11B1
SCHEMBL9888407 0.82 NPC1 (0.41) NPC1USP2GAAALOX15RAD51
SCHEMBL1570778 0.81 GFER (0.49) NPC1USP2GAAALOX15RAD51
SCHEMBL9913554 0.81 IMPDH2 (0.44) NPC1USP2GAAALOX15RAD51
SCHEMBL1571215 0.81 SLC6A4 (0.55) NPC1CTNNB1WNT3ACYP17A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198274-B2 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2012-06-12 US disclosed
US-8198274-B2 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2012-06-12 US disclosed
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC 2010-01-21 US disclosed
WO-2010006945-A1 SUBSTITUTED INDOLYL AND INDAZOLYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2010-01-21 WO disclosed
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof MAOB, MAOA, TPH1 NPC1 707/4885USP2 4363/4885GAA 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.